Las Vegas, NV – (NewMediaWire) – January 12, 2022 – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a Company focused on the development of novel technologies in the healthcare and biotech sectors, today announced the appointment of Eugene Cha to its Board of Directors.
Eugene Cha is a seasoned attorney who specializes in cross-border business and investment transactions, as well as having served as a board member to numerous international businesses. Mr. Cha’s experience as an independent board member includes serving on the boards of financial services and fund management companies, including Founder Fubon Fund Managements Co., Ltd., Xiaman Bank, and Core Pacific Yamaichi Securities Co., Ltd., and on the boards of biotechnology companies and a conglomerate which owns publicly listed petrochemical and construction companies in Taiwan. In addition, Mr. Cha previously served as chief counsel for Core Pacific Group, a major conglomerate in Taiwan. Mr. Cha earned his Bachelor of Laws degree from National Taiwan University and a Master of Comparative Law degree from the University of Michigan.
“Mr. Cha has practiced law since 1984 in New York, Taipei and Beijing. Since 2005, Mr. Cha has served as an independent director for seven companies in the U.S., China, Hong Kong, and Taiwan. We are delighted and honored to welcome Mr. Cha to Hestia Insight,” said Edward C. Lee, CEO and Chairman of Hestia Insight.Mr. Lee continued, “We welcome Eugene to our board, not only for his extensive international legal and business experience, but also because his role as an independent director will greatly assist with Hestia Insight’s management and corporate governance.
About Hestia Insight Inc.
Hestia Insight Inc. (“Hestia Insight” and the “Company”) is focused primarily on the healthcare and biotech sectors through the Company’s two wholly owned operating subsidiaries, Hestia Investments Inc. (“Hestia Investments”), and HSTA Health Inc. (“HSTA Health”). Hestia Investments provides strategic consulting, medical supply sales and marketing support, management, and capital markets advisory services for select micro, small and medium sized companies within the healthcare and biotech sectors. HSTA Health provides healthcare management and patient services and develops new healthcare technologies for neurological and psychiatric disorders. The Company is positioned to make strategic acquisitions of emerging growth companies with unique sciences and technologies.The Company intends to pursue the acquisition and development of healthcare related technologies in the healthcare and biotech sectors through acquisition, licensing or joint ventures. The Company will also consider a third avenue of investing in certain technologies. The Company entered the healthcare sector to explore emerging healthcare technologies, especially growth companies that own and develop unique sciences and technologies.
For more information about Hestia Insight, please visit the Company’s website: www.hestiainsight.com
Hestia Insight Investor Relations: investors.hestiainsight.com
Facebook: Hestia Insight Inc.
LinkedIn: Hestia Insight Inc.
Hestia Insight is subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, and, in accordance with the Securities Exchange Act, the Company files periodic reports, documents, and other information with the SEC relating to our business, financial statements, and other matters. These filings are available to the public on the Commission’s website at http://www.sec.gov
Safe Harbor Provision
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created thereby.All statements other than statements of historical fact contained herein, including, without limitation, statements regarding the Company’s future financial position, business strategy, plans and objectives, growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may”, “will”, “expects”, “intends”, “plans”, “projects”, “estimates”, “anticipates”, or “believes” or the negative thereof or any variation thereon or similar terminology or expressions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can provide no assurance that such expectations will prove to have been correct. Important factors that could cause actual results to differ materially from the Company’s expectations include, but are not limited to, those factors set forth in the Company’s Annual Report on Form 10-K for the year ended November 31, 2020 and its other filings and submissions with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the Company assumes no obligation to update or revise any forward-looking statements.
Investor Relations Contact: